Study on rhTPO for ADC-Induced Thrombocytopenia in Solid Tumors

INTERVENTION: Prevention Team:Administer rhTPO 300 IU/kg by continuous subcutaneous injection;Control group:Do not use rhTPO for preventive medication. If PLT drops below 50 X10^9/L during this period, use rhTPO for rescue treatment (300 IU/kg/day for no more than 14 days). Stop the medication once PLT reaches 100 X10^9/L or higher.; CONDITION: Adult solid tumors who experience grade =2 thrombocytopenia (PLT < 75×10^9/L) as a result of ADC drug treatment (including but not limited to T‐DM1, T‐DXd, RC‐48, SHR‐A1811, SG, Dato‐DXd, SAC‐TMT, EV, TV, etc., with or without combined chemotherapy/targeted/immunotherapy). PRIMARY OUTCOME: Proportion of patients who can effectively maintain platelet counts at the end of the second treatment cycle; INCLUSION CRITERIA: 1. Age range: 18‐75 years old; both men and women are acceptable; 2. ECOG PS score: 0‐1 points; 3. Patients with solid tumors who experience a reduction in platelets at level >= 2 due to ADC therapies (including but not limited to T‐DM1, T‐DXd, RC‐48, SHR‐A1811, Dato‐DXd, SKB264, EV, TV, etc., either in combination or without chemotherapy/targeted/immunotherapy), and for whom further treatment for at least 2 cycles is expected; 4. Expected survival period >= 6 months; 5. The functional level of major organs must meet the following criteria (based on the normal values of the clinical trial center): (1) Hematology: absolute neutrophil count (ANC) >= 1.5 X10^9/L; hemoglobin (Hb) >= 90 g/L; (2) Clinical biochemistry: total bilirubin (TBIL) <= 1.5 Xupper limit of normal (ULN); in the absence of liver metastases, ALT, AST, or ALP <= 3 XULN; in the presence of liver metastases, ALT, AST, or ALP <= 5 XULN; serum creatinine <= 1.5 XULN; (3) Coagulatio